TNGX
Tango Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.83B
P/E Ratio
—
EPS
$-0.87
Beta
1.31
52W High
$22.20
52W Low
$1.03
50-Day MA
$15.09
200-Day MA
$9.69
Dividend Yield
—
Profit Margin
-162.90%
Forward P/E
—
PEG Ratio
—
About Tango Therapeutics Inc
Tango Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of targeted therapies aimed at addressing significant unmet needs in cancer treatment, particularly through the innovative concept of synthetic lethality. With a diverse pipeline of promising drug candidates, Tango is well-positioned to lead advancements in precision oncology, focusing on collaborative partnerships with leading research institutions to enhance its scientific capabilities. The company's strategic vision is to transform cancer care and improve patient outcomes, positioning it as a key player in the evolution of treatment paradigms in oncology.
Fundamentals
| Revenue (TTM) | $62.38M |
| Gross Profit (TTM) | $-69.78M |
| EBITDA | $-109.01M |
| Operating Margin | -178.40% |
| Return on Equity | -37.20% |
| Return on Assets | -19.50% |
| Revenue/Share (TTM) | $0.54 |
| Book Value | $2.55 |
| Price-to-Book | 8.92 |
| Price-to-Sales (TTM) | 45.29 |
| EV/Revenue | 44.51 |
| EV/EBITDA | -0.91 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $142.69M |
| Float | $67.74M |
| % Insiders | 1.27% |
| % Institutions | 121.14% |
Historical Volatility
HV 10-Day
76.47%
HV 20-Day
58.22%
HV 30-Day
108.45%
HV 60-Day
95.27%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($21.40 target)
1
Strong Buy9
Buy1
HoldData last updated: 4/9/2026